Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
07 Februar 2024 - 12:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 6, 2024
________________
NOVO NORDISK A/S
(Exact name of
Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives
and associated persons
Bagsværd, Denmark, 6 February 2024 — This company announcement discloses
the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons
in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have reported the
transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by
the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 |
Reason for the notification |
| a) |
Position/status |
President and CEO |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 818.66 |
35 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
35 shares
DKK 818.66 |
| e) |
Date of the transaction |
2024-02-05 |
| f) |
Place of the transaction |
(AQEA) AQUIS EXCHANGE EUROPE AUCTION ON DEMAND (AOD) |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 |
Reason for the notification |
| a) |
Position/status |
President and CEO |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 801.37 |
309 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
309 shares
DKK 801.37 |
| e) |
Date of the transaction |
2024-02-05 |
| f) |
Place of the transaction |
(AQEU) AQUIS EXCHANGE EUROPE |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 |
Reason for the notification |
| a) |
Position/status |
President and CEO |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 808.08 |
8,510 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
8,510 shares
DKK 808.08 |
| e) |
Date of the transaction |
2024-02-05 |
| f) |
Place of the transaction |
(BEUP) CBOE EUROPE - DXE PERIODIC (NL) |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 |
Reason for the notification |
| a) |
Position/status |
President and CEO |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 805.90 |
355 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
355 shares
DKK 805.90 |
| e) |
Date of the transaction |
2024-02-05 |
| f) |
Place of the transaction |
(CEUD) CBOE EUROPE - DXE DARK ORDER BOOK (NL) |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 |
Reason for the notification |
| a) |
Position/status |
President and CEO |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 811.02 |
35,585 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
35,585 shares
DKK 811.02 |
| e) |
Date of the transaction |
2024-02-05 |
| f) |
Place of the transaction |
(CEUX) CBOE EUROPE - DXE ORDER BOOKS (NL) |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 |
Reason for the notification |
| a) |
Position/status |
President and CEO |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 810.89 |
3,962 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
3,962 shares
DKK 810.89 |
| e) |
Date of the transaction |
2024-02-05 |
| f) |
Place of the transaction |
(MCSE) NASDAQ COPENHAGEN A/S - AUCTION ON DEMAND |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 |
Reason for the notification |
| a) |
Position/status |
President and CEO |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 818.83 |
159 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
159 shares
DKK 818.83 |
| e) |
Date of the transaction |
2024-02-05 |
| f) |
Place of the transaction |
(SGMV) SIGMA X EUROPE AUCTION BOOK |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 |
Reason for the notification |
| a) |
Position/status |
President and CEO |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 820.50 |
26 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
26 shares
DKK 820.50 |
| e) |
Date of the transaction |
2024-02-05 |
| f) |
Place of the transaction |
(TQEA) TURQUOISE EUROPE - LIT AUCTIONS |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 |
Reason for the notification |
| a) |
Position/status |
President and CEO |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 808.69 |
574 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
574 shares
DKK 808.69 |
| e) |
Date of the transaction |
2024-02-05 |
| f) |
Place of the transaction |
(TQEX) TURQUOISE EUROPE |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 |
Reason for the notification |
| a) |
Position/status |
President and CEO |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 809.76 |
129,916 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
129,916 shares
DKK 809.76 |
| e) |
Date of the transaction |
2024-02-05 |
| f) |
Place of the transaction |
(XCSE) NASDAQ COPENHAGEN A/S |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 |
Reason for the notification |
| a) |
Position/status |
President and CEO |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 807.51 |
569 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
569 shares
DKK 807.51 |
| e) |
Date of the transaction |
2024-02-05 |
| f) |
Place of the transaction |
(XPAC) POSIT AUCTION |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 |
Reason for the notification |
| a) |
Position/status |
President and CEO |
| b) |
Initial notification/Amendment |
Amendment to company announcement no. 8 / 2024 which erroneously stated 10,000 shares too many, cf. also Remuneration Report 2023, page 20 |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Other transaction (transfer of shares in accordance with Long Term incentive programme) |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 0.00 |
139,422 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
139,422 shares
DKK 0.00 |
| e) |
Date of the transaction |
2024-01-31 |
| f) |
Place of the transaction |
Outside a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Martin Holst Lange |
| 2 |
Reason for the notification |
| a) |
Position/status |
Executive Vice President |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 797.80 |
16,000 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
16,000 shares
DKK 797.80 |
| e) |
Date of the transaction |
2024-02-05 |
| f) |
Place of the transaction |
NASDAQ COPENHAGEN A/S |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Tania Sabroe |
| 2 |
Reason for the notification |
| a) |
Position/status |
Executive Vice President |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 797.10 |
21,264 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
21,264 shares
DKK 797.10 |
| e) |
Date of the transaction |
2024-02-05 |
| f) |
Place of the transaction |
NASDAQ COPENHAGEN A/S |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Marcus Schindler |
| 2 |
Reason for the notification |
| a) |
Position/status |
Executive Vice President |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 809.71 |
36,392 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
36,392 shares
DKK 809.71 |
| e) |
Date of the transaction |
2024-02-06 |
| f) |
Place of the transaction |
NASDAQ COPENHAGEN A/S |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Camilla Sylvest |
| 2 |
Reason for the notification |
| a) |
Position/status |
Executive Vice President |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 809.64 |
74,915 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
74,915 shares
DKK 809.64 |
| e) |
Date of the transaction |
2024-02-05 |
| f) |
Place of the transaction |
NASDAQ COPENHAGEN A/S |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated Person |
Henrik Ehlers Wulff |
| 2 |
Reason for the notification |
| a) |
Position/status |
Executive Vice President |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer |
| a) |
Name |
Novo Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| |
Identification code |
Novo Nordisk B DK0062498333 |
| b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
| |
Price(s) |
Volume(s) |
|
| |
DKK 823.09 |
60,000 shares |
|
| |
|
|
|
| |
|
|
|
| d) |
Aggregated information
|
60,000 shares
DKK 823.09 |
| e) |
Date of the transaction |
2024-02-06 |
| f) |
Place of the transaction |
NASDAQ COPENHAGEN A/S |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in
Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering
scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs
about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen
(Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram,
X, LinkedIn and YouTube.
Contacts for further information
| Media: |
|
| |
|
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com |
Elizabeth DeLuca (US)
+1 609 580 9868
edel@novonordisk.com |
| |
|
| Investors: |
|
| |
|
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com |
Frederik Taylor Pitter
+45 375 8259
fptr@novonordisk.com |
| |
|
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
| |
|
Sina Meyer
+45 379 6656
azey@novonordisk.com |
|
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company announcement No 11 / 2024 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 6, 2024 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
